Mark Bamforth has founded, built, and sold three contract development and manufacturing organizations over the last 12 years with private equity partners.

Gallus Biopharmaceuticals focused on monoclonal antibodies, Brammer Bio produced viral vectors for gene therapy and Arranta Bio produced microbiome, plasmid and mRNA vaccines. In total, these companies created over 1200 jobs, enabled over 100 clinical trial projects for clients, and delivered two commercial products.

Previously, Bamforth spent 22 years at Genzyme, latterly running a 12-site clinical and manufacturing operation supporting over 20 commercial therapeutics, and a pharmaceutical CMO business. His career began as a petroleum engineer with Britoil, then as a chemical engineer with Whitbread.

Bamforth serves on the boards of Continuus Pharma, Enterobiotix, Inceptor Bio, Pneumagen, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.